Innogenetics was founded on 18 July 1985, by Erik Tambuyzer, Hugo Van Heuverswyn and Rudi Mariën. In 1992, the company launched the first commercial tests for cystic fibrosis in Europe (INNO-LiPA CFTR) and in 1993 the first commercial test for Hepatitis C virus (HCV) genotyping worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-Amyloid and in 2002 the first commercial test for Hepatitis B virus (HBV) genotyping (INNO-LiPA HBV Genotyping).